PHSE

Pharmhouse Corp

Pharmhouse Corp (PHSE) is rated C (2.3/5) on Deltasharpe Prism, scored against Consumer Cyclical sector peers. Its strongest pillar is Growth (B+); its weakest is Revisions (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C
Factor Score 2.3 / 5.0
Growth
B+
Factor Score 3.6 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
D+
Factor Score 1.7 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.0
Rev Growth YoY 190.8%
Gross Margin 13.5%
Price Return 3M -62.5%
Price Return 12M -52.5%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 6.6K
ROE -56.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C (2.3) B+ (3.6) D+ (1.7) C- (2.0) D+ (1.7) C (2.3)
2026-08-04 C (2.3) B+ (3.6) D+ (1.7) C- (2.1) D+ (1.8) C (2.3)
2026-08-03 C (2.3) C+ (2.7) C- (2.0) C (2.3) D+ (1.8) C (2.2)
2026-08-02 C (2.3) C+ (2.7) C- (2.0) C (2.2) D+ (1.8) C (2.2)